(MedPage Today) — PHILADELPHIA — Most multi-food allergic children succeeded in longer term regular dietary consumption whether treated with oral immunotherapy (OIT) or omalizumab (Xolair) alone, results from stage 3 of the OUtMATCH trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/aaaai/120102
Author :
Publish date : 2026-03-01 19:21:00
Copyright for syndicated content belongs to the linked Source.
